Browse the evidence

A BMI greater than 30 kg/m^2 is considered diagnostic for obesity.

Practitioners should use BMI as a key metric for diagnosing obesity.

The fraction of available calories from protein in the US food supply has decreased by ~1% since the early 1970s.

Awareness of changes in dietary composition over time is important for nutritional guidance.

More people around the world now have obesity than suffer from starvation.

This indicates a need for urgent public health interventions to address obesity.

The energy available in the food supply increased much more than population needs.

This suggests that dietary guidelines may need to be adjusted to account for excess energy availability.

Substantial investments in coordinated nutrition and agricultural research are needed to transform the food system.

This highlights the importance of policy and research in addressing obesity and food security.

The mean cumulative intervention costs for the intensive lifestyle intervention (ILI) were $11,275 per person, compared to $887 for standard diabetes support and education (DSE), resulting in ILI costing $6,666 more per person than DSE.

Practitioners should consider the higher costs associated with intensive lifestyle interventions compared to standard education.

The additional quality-adjusted life years (QALYs) gained by ILI were not statistically significant, with values of 0.17 and 0.16 measured by SF-6D and Feeling Thermometer, respectively.

The lack of statistically significant QALY gains suggests that intensive lifestyle interventions may not provide additional health benefits over standard education.

No significant findings emerged in men and women separately, in the African-American subset, or for the 8-10 week outcomes.

Results may not be generalizable across all demographics, highlighting the need for tailored approaches.

Management of GLP-1RA adverse events lacks evidence-based support.

Healthcare providers should be cautious in applying management strategies for GLP-1RA adverse events due to the lack of evidence.

Rifampicin inhibits body weight gain in high-fat diet-fed mice.

Rifampicin may be considered as a potential treatment for obesity in high-fat diet contexts.

Mice receiving NN501 display a more gradual weight regain and no compensatory hyperphagic response after treatment cessation.

NN501 may help in maintaining weight loss without the rebound effects seen with other treatments.

Current clinical evidence does not demonstrate therapeutic benefit of GLP-1RAs in ALS.

Clinicians should be cautious in prescribing GLP-1RAs for ALS due to lack of evidence.

Women's adjusted odds of diagnosis were far higher than men's (95% confidence interval 1.66-1.75).

Healthcare providers should consider gender disparities in obesity diagnosis when assessing patients.

Obesity is defined as a BMI of more than 30 kg/m2 and is a prevalent chronic disease.

Healthcare practitioners should recognize obesity as a significant health challenge.

The incidence of obesity has nearly trebled since 1975.

Public health initiatives must address the rising rates of obesity.

There were no reports of pharmacotherapies for weight management in the studies reviewed.

Practitioners should be aware that pharmacotherapy options are not currently reported for this population.

Hepatotoxicity is not a widely recognized complication of tirzepatide.

Awareness of potential liver injury should be increased among healthcare providers prescribing tirzepatide.

The previous version of the guideline did not include a literature review for obesity surgery due to limited resources, and it references an existing guideline for obesity surgery.

Clinicians should be aware of the referenced guidelines for obesity surgery when making treatment decisions.

More work is needed to understand the mechanisms and full potential of antiobesity medicines in cancer.

Ongoing research is essential to fully understand the implications of antiobesity medications on cancer.

The present study did not find an association between resistance training (RT) and all-cause mortality.

Resistance training may not significantly impact overall mortality risk.

Neither meeting the guidelines nor monthly RT volume was associated with all-cause mortality in adjusted models.

Adherence to resistance training guidelines or volume does not appear to influence mortality risk.

Current glucose-lowering therapies for Type 2 diabetes show no benefit in reducing the risk of macrovascular events.

Clinicians should reconsider the reliance on glucose-lowering therapies for cardiovascular protection.

There is a need for more high-quality, large, prospective controlled research to elucidate the role of dietary structure with different fat to carbohydrate ratios across the life cycle of diabetes.

Future research should focus on dietary ratios to better inform diabetes management strategies.

There was a statistically significant decrease in counselor feedback duration from the first to second quarter and from the second to third quarter.

Understanding the timing of feedback can help optimize counselor training and intervention design.